Base Year
Historical Year
Forecast Year
The cervical dystonia market size is expected to grow at a CAGR of 5.8% during the forecast period of 2024-2032. The market is driven by the advancements in treatment options and diagnostic methods along with the heightened awareness around the condition across 8 major markets.
Cervical dystonia is a neurological condition that causes involuntary contraction of the neck muscles. It can make the head and neck twist or turn into abnormal positions that can be painful to the patient. The prevalence of cervical dystonia is estimated to be 5 to 30 cases for every 100,000 individuals. In the United States, the incidence of the condition is 1.18 per 100,000 individuals annually. The number of patients suffering from this movement disorder are rising steadily, which is projected to fuel the cervical dystonia market growth in the coming years.
The market is experiencing a rise in the number of approvals from health regulatory authorities which is positively influencing the market landscape. In August 2023 , the United States Food and Drug Administration (FDA) approved Daxxify® (daxibotulinumtoxinA- lanm) to treat cervical dystonia in adults. The product, developed by a United States-based pharmaceutical company Revance Therapeutics Inc., is the first peptide-formulated and long-lasting neuromodulator designed to provide relief to patients suffering from the condition. The launch of such innovative treatment therapeutics is expected to bolster the cervical dystonia market demand.
The market is also driven by the rise in geriatric population prone to movement disorders. Moreover, increased investments by biopharmaceutical companies in research and development projects is likely to aid in the expansion of the market share. There has been a significant effort to increase awareness among the public about cervical dystonia. This includes the importance of early diagnosis, leading to improved outcomes for patients.
| Key Trends | Description |
| Emergence of Neuromodulation Therapies | Neuromodulation techniques, such as deep brain stimulation (DBS), have emerged as potential treatment options for patients with cervical dystonia. |
| Improved Diagnostic Technologies | Advances in imaging techniques and the development of genetic markers have increased the diagnostic accuracy for cervical dystonia. This facilitates earlier intervention and improves patient outcomes. |
| Intensive Research Initiatives | Ongoing research aims to understand the underlying causes and mechanisms of cervical dystonia in order to develop novel therapeutics. |
| Personalized Medicine Approaches | Efforts are being made to customize treatments based on severity of symptoms, and response to previous treatments. The growing demand for personalized approaches will optimize outcomes and minimize side effects. |
Market Breakup by Type
Based on market segmentation by type, the report includes retrocollis, anterocollis, laterocollis, and torticollis, among others. Retrocollis refers to backward head tilting, anterocollis to forward tilting, laterocollis to lateral tilting, and torticollis to twisting of the neck. Each subtype may require specific interventions to manage the symptoms.
Market Breakup by Therapy
By therapy, the cervical dystonia market share is divided into oral therapy, intravenous treatment, and surgery, among others. These therapy options help to address the diverse needs of the patients suffering from cervical dystonia.
Market Breakup by End User
The market segmentation by end users includes hospitals, homecare, specialty clinics, and others.
Market Breakup by Region
The cervical dystonia market report offers an exhaustive analysis of the regional markets expected to witness significant market growth in the forecast period. The regional segmentation includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America holds a high market value which can be attributed to the rising geriatric population in the region. Moreover, the presence of an advanced healthcare system and the increased investment by pharmaceutical companies to develop effective therapeutics is propelling the market share in this regional market.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapy |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032, driven by the advancements in treatment options and diagnostic methods across the 8 major markets.
Increased investments supporting the development of effective therapeutics and rising healthcare expenditure are fuelling market demand.
One of the significant trends in the market is the growth in approvals by the health regulatory agencies. In August 2023, the Food and Drug Administration (FDA) approved Revance Therapeutics’ Daxxify® (daxibotulinumtoxinA- lanm) to treat cervical dystonia in adults.
Based on the type, the market is segmented into retrocollis, anterocollis, laterocollis, and torticollis, among others.
Major end users of the market include hospitals, homecare, specialty clinics, and others.
Therapies for cervical dystonia include oral therapy, intravenous treatment, and surgery, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China.
Key players involved in the market are AbbVie Inc., Ipsen Pharma, Galderma SA, Revance Therapeutics Inc., AEON Biopharma, Merz Pharmaceuticals, US World Meds, Tercica Inc., Boston Scientific Corporation, Allergan Inc., and Solstice neurosciences lnc.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share